Enterostomy
Conditions
Keywords
High-Output Enterostomy, Pasireotide, Somatostatin Analogues
Brief summary
During rectal or complex digestive surgery with multiple digestive resections and anastomosis, the creation of enterostomy is a common procedure. In France, it is estimated that 20000 patients have an ileostomy and 16000 new digestive stomas are formed each year with approximately 30% of enterostomy. Enterostomy might sometimes give high-output not controlled with usual medical treatment (e.g loperamide ± codeine) and exposes the patients to important hydro-electrolytic loss leading to a risk for dehydration, electrolyte abnormalities and acute renal failure. This risk implies parenteral correction which may extend hospital stay and delay home return. Somatostatin analogues (octreotide, lanreotide and pasireotide) could reduce digestive secretions and decrease digestive peristalsis. Nevertheless, somatostatin analogues are not routinely used for the treatment of patients with high-output enterostomy and their efficacy in the indication (off-label) was only tested in small case series. Pasireotide (SOM230, SIGNIFOR®) is currently indicated for the treatment of patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed. As the efficacity of pasireotide in patients with high-output enterostomy refractory to usual medical treatment associated with an oral fluid restriction has never been demonstrated before, there is a need to perform a pilot, double-blind, randomized, placebo-controlled trial evaluating its impact on reduction of the effluent volume.
Interventions
DRUGPasireotide
Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
DRUGPlacebo
Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
Sponsors
Hospices Civils de Lyon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and Female patients ≥ 18 years old ; * Patients who underwent an intestinal surgery with enterostomy repair in the three weeks preceding the inclusion ; * Patients with high-output ileostomy or jejunostomy \> 1000 ml/24h ; * Patients with failure of treatment combining oral fluid restriction and loperamide (up to 8 capsules/24h) +/- codeine syrup (10 mg x 3/24h) during 5 days ; * Patients who gave its written informed consent to participate to the study ; * Patients affiliated to a social insurance regime.
Exclusion criteria
* Male and Female patients \< 18 years old ; * Patients who did not give its written informed consent to participate to the study ; * Patients who received somatostatin analogues during the month before inclusion ; * Patients with symptomatic cholelithiasis or acute or chronic pancreatitis ; * Patients with uncontrolled diabetes (with HbA1c (glycated hemoglobin) \> 8%) ; * Patients who are hypothyroid and not on adequate replacement therapy ; * Patients who have congestive heart failure (NYHA (New York Heart Association) Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, advanced heart block or a history of clinically significant bradycardia or acute myocardial infarction within the 6 months preceding randomization ; * Patients with history of syncope or family history of idiopathic sudden death ; * Patients with screening or baseline (predose) : QT interval corrected for heart rate using Fridericia's correction (QTcF) QTcF \> 450 msec (male), QTcF \> 460 msec (female) (QT interval corrected for heart rate using Fridericia's correction) ; * Patients with not corrected hypokalaemia and/or hypomagnesaemia ; * Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis, or patients with alanine transaminase/aspartate transaminase (ALT/AST) \> 2 x Upper Limit of Normal (ULN), serum bilirubin \> 2 x ULN ; * Patients with Child-Pugh C cirrhosis ; * Female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control ; * Patients with abnormal coagulation (PT and/or APTT elevated by 30% above normal limits) or patients receiving anticoagulants that affect PT (prothrombin time) or activated partial thromboplastin time (APTT) ; * Patients with known hypersensitivity to somatostatin analogues or any other component of the pasireotide LAR ; * Patients under guardianship ; * Patients nonaffiliated to a social insurance regime.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare the efficacy of pasireotide versus placebo in reduction of high-output | Evaluated 72 hours after first injection of treatment | Decrease of enterostomy output (ml/24H)within the 72 hours after first injection of treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estimate the success rate of pasireotide and placebo | 1 week after first injection of treatment | Number of normal renal function patients in both arms with an enterostomy output than 800 millimeters (mL) /24h within a week after first injection of treatment allowing discontinuation of intravenous perfusion. |
| Compare the decrease in the length of hospitalization with pasireotide versus placebo | 1 month after the end of treatment | Duration of hospitalization in days in both arms |
| Compare the incidence of premature closure of stoma due to high-output with pasireotide versus placebo | 2 months after enterostomy creation | Rate of premature closure of stoma due to high-output (before 2 months after creation) in both arms |
| Evaluate the economic impact of pasireotide in this indication | 2 months from the inclusion of the patient in the study | Costs of taking care of patients from French Public Health Insurance perspective in both arms |
| Incidence of treatment - Emergent Adverse Events | during treatment (4 days), one week, two weeks, three weeks and one month after treatment | Nature, number and grade of adverse events observed throughout the study |
Countries
France
Outcome results
None listed